{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-021199","form_type":"8-K","ticker":"ALXO","cik":"0001810182","company_name":"ALX ONCOLOGY HOLDINGS INC","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.746276+00:00","generated_at":"2026-06-15T04:35:08.675204+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ALX Oncology Q1 net loss $30.2M ($0.74/sh); cash $256.2M; evorpacept trials advance","bullets":["GAAP net loss $30.2M vs $24.5M YoY; non-GAAP net loss $23.8M vs $19.0M.","Cash, equivalents and investments $256.2M; runway through mid-2025 with $40M term loan available.","R&D expenses $24.8M, up 45% YoY driven by more active trials and manufacturing.","Entered clinical collaboration with Sanofi to test evorpacept + SARCLISA in relapsed/refractory multiple myeloma.","Top-line data expected H2 2023 from ASPEN-06 (gastric cancer) and ASPEN-02 (MDS) trials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-021199","json":"https://secwatch.observer/filing/0000950170-23-021199.json","markdown":"https://secwatch.observer/filing/0000950170-23-021199.md","text":"https://secwatch.observer/filing/0000950170-23-021199.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023021199/0000950170-23-021199-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023021199/alxo-20230511.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:35:08.675204+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c0da82f22245302c9f80dcf5b5e83cddea7f9094","claim":"ALX ONCOLOGY HOLDINGS INC reported financial results for first quarter ended March 31, 2023.","evidence_excerpt":"On May 11, 2023, ALX Oncology Holdings Inc. (the \"Company\"), issued a press release announcing its financial results for the first quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1810182/000095017023021199/0000950170-23-021199-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}